Salix Pharmaceuticals
(https://salix.com) 📸 Data Snapshot: June 19, 2026Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
The homepage hero section promises a ‘Promising Pipeline’ and ‘Proven Treatments,’ signaling a forward-looking, innovation-driven company. However, the sub-pages fail to detail a current pipeline, instead retreating into a historical timeline that has not been updated in seven years. There is a significant disconnect between the ‘No Finish Line’ slogan and a corporate history that appears to stop in 2019. Furthermore, the promise of ‘Committed Care’ and ‘Building a community’ is never backed by patient outcomes or community metrics in the supporting content.
Semantic Coherence is read from the heading hierarchy first: what each page announces in its H1 and headings, then whether the body actually delivers on it. Below is the structure the engine mapped, followed by the clean text to check for drift between promise and reality.
🏗️ Semantic Structure — heading hierarchy & page identity (the promise the page makes)
HOMEPAGE Home | Salix Pharmaceuticals (https://salix.com)
Home | Salix Pharmaceuticals
Learn about Salix, one of the largest specialty pharmaceutical companies in the world, and our ongoing pursuit of life-changing GI healthcare for all.
NAV_HEADER_HEADING_REPEATED_FOOTER Contact Us | Salix Pharmaceuticals (https://salix.com/about-us/contact-us/)
Contact Us | Salix Pharmaceuticals
Find media contact information for Salix Pharmaceuticals, including our phone number and mailing address.
NAV_HEADER_HEADING_REPEATED_BODY About Us | Salix Pharmaceuticals (https://salix.com/about-us/)
About Us | Salix Pharmaceuticals
Read about Salix’s commitment to preventing and treating GI diseases such as hepatic encephalopathy, IBS-D, opioid-induced constipation, and ulcerative colitis.
NAV_HEADER_HEADING_REPEATED_BODY History | Salix Pharmaceuticals (https://salix.com/about-us/history/)
History | Salix Pharmaceuticals
Look back at the history of Salix, from our founding in 1989 up to the present.
📝 The Narrative — clean text per page (homepage promise vs. sub-page reality)
HOMEPAGE · THIN (https://salix.com) Home | Salix Pharmaceuticals
SeeProductList [H3] Proven Treatments Effective solutions for a wide range of patients Discover The Future [H3] Promising Pipeline Rigorous research and development to advance innovative products View The Good [H3] Committed Care Building a community based on integrity and mutual respect
SUB-PAGE · THIN (https://salix.com/about-us/contact-us/) Contact Us | Salix Pharmaceuticals
[H1] Visit, Ask, Connect [H4] Corporate Headquarters Salix Pharmaceuticals is located in Bridgewater, New Jersey, about an hour south of New York City and an hour north of Philadelphia. 400 Somerset Corporate Blvd.Bridgewater, NJ 08807 USAPhone: 1-800-321-4576 [H4] Customer Support Phone: 800-321-4576 [H4] U.S. Medical Information Submit Medical Inquiry [H4] For Media Inquiries Salix PharmaceuticalsEmail: salixcommunications@salix.com
SUB-PAGE · THIN (https://salix.com/about-us/) About Us | Salix Pharmaceuticals
See Compliance Commitment [H3] The Highest Standards We realize that operating with transparency develops and fosters trust Contact Us [H3] Visit, Ask, Connect Have a medical, investor, or media-related question? JOIN THE JOIN THE A long history of
SUB-PAGE (https://salix.com/about-us/history/) History | Salix Pharmaceuticals
[H1] Every Journey Starts With a Step We started ours in 1989 when our founders, Randy W. Hamilton and Lorin K. Johnson, PhD, realized the need for more effective gastrointestinal solutions. Since then, Salix hasn’t stopped moving forward. [H4] 1989 - Salix Pharmaceuticals is founded in Sunnyvale, California [H4] 1990 - COLAZAL® (balsalazide disodium) is licensed [H4] 1996 - XIFAXAN® (rifaximin) is licensed [H4] 2000 - Operations move to Raleigh, North Carolina- COLAZAL® (balsalazide disodium) receives FDA approval [H4] 2004 - XIFAXAN® (rifaximin) 200 mg receives FDA approval [H4] 2006 - MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) receives FDA approval [H4] 2008 - APRISO® (mesalamine granules) receives FDA approval- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval [H4] 2009 - OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) receives FDA approval Prescribing Information, including BOXED WARNING. [H4] 2010 - XIFAXAN® (rifaximin) 550 mg receives FDA approval [H4] 2013 - UCERIS® (budesonide) extended-release tablets receives FDA approval- GIAZO® (balsalazide disodium) 1.1g tablets receive FDA approval [H4] 2014 - Salix acquires Santarus- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for an additional indication [H4] 2015 - UCERIS® (budesonide) rectal foam receives FDA approval- XIFAXAN® (rifaximin) 550 mg receives FDA approval for additional indication- Valeant acquires Salix- Operations begin moving to Bridgewater, New Jersey, our current location [H4] 2016 - Salix launches RELISTOR® (methylnaltrexone bromide) tablets [H4] 2017 - Salix scales up sales force by nearly 40 percent [H4] 2018 - Valeant changes name to Bausch Health- Salix launches PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) [H4] 2019 - Salix celebrates three decades of GI solutions- Bausch Health completes acquisition of certain assets of Synergy Pharmaceuticals, including Trulance (plecanatide) Prescribing Information, including BOXED WARNING. - Salix Pharmaceuticals announces inaugural scholarship program to commemorate its 30th anniversary
This page presents a snapshot of public data from Salix Pharmaceuticals, captured on June 19, 2026, to show how machine logic reads Semantic Coherence signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Salix Pharmaceuticals: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://salix.com to view the most current version of its content and see directly what this company is about and what it offers.